bridgecrew-perf6 / antibody-and-antiviral-deployment Goto Github PK
View Code? Open in Web Editor NEWThis project forked from opensafely/antibody-and-antiviral-deployment
While vaccines remain the best strategy to prevent COVID-19, mAbs could potentially benefit certain vulnerable populations before or after exposure to SARS-CoV-2, such as the unvaccinated or recently vaccinated high-risk patients.
License: MIT License